Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
An important aspect of ocular herpes simplex virus type 1 (HSV-1) vaccine development is identification of an appropriate adjuvant capable of significantly reducing both virus replication in the eye and explant reactivation in trigeminal ganglia. We showed recently that a recombinant HSV-1 vaccine expressing interleukin-4 (IL-4) is more efficacious against ocular HSV-1 challenge than recombinant viruses expressing IL-2 or gamma interferon (IFN-gamma) (Y. Osorio and H. Ghiasi, J. Virol. 77:5774-5783, 2003). We have now constructed and compared recombinant HSV-1 viruses expressing IL-12p35 or IL-12p40 molecule with IL-4-expressing HSV-1 recombinant virus. BALB/c mice were immunized intraperitoneally with IL-12p35-, IL-12p40-, IL-12p35+IL-12p40-, or IL-4-expressing recombinant HSV-1 viruses. Controls included mice immunized with parental virus and mice immunized with the avirulent strain KOS. The efficacy of each vaccine in protecting against ocular challenge with HSV-1 was assessed in terms of survival, eye disease, virus replication in the eye, and explant reactivation. Neutralizing antibody titers, T-cell responses, and expression of 32 cytokines and chemokines were also evaluated. Mice immunized with recombinant HSV-1 expressing IL-12p35 exhibited the lowest virus replication in the eye, the most rapid virus clearance, and the lowest level of explant reactivation. The higher efficacy against ocular virus replication and explant reactivation correlated with higher neutralizing antibody titers, cytotoxic-T-lymphocyte activities, and IFN-gamma expression in recombinant HSV-1 expressing IL-12p35 compared to other vaccines. Mice immunized with both IL-12p35 and IL-12p40 had lower neutralizing antibody responses than mice immunized with IL-12p35 alone. Our results confirm that recombinant virus vaccines expressing cytokine genes can enhance the overall protection against infection, with the IL-12p35 vaccine being the most efficacious of those tested. Collectively, the results support the potential use of IL-12p35 as a vaccine adjuvant, without the toxicity-associated concerns of IL-12.
Osorio
Yanira
Y
Center for Neurobiology and Vaccine Development, Cedars-Sinai Medical Center Burns and Allen Research Institute, D2024, 8700 Beverly Blvd., Los Angeles, CA 90048, USA.
Ghiasi
Homayon
H
D000276:Adjuvants, Immunologic; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D018925:Chemokines / Q000032:analysis; D016207:Cytokines / Q000032:analysis; D004195:Disease Models, Animal; D005260:Female; D022301:Herpes Simplex Virus Vaccines / Q000276:immunology*; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D018664:Interleukin-12 / Q000235:genetics / Q000276:immunology*; D053765:Interleukin-12 Subunit p35; D053762:Interleukin-12 Subunit p40; D015847:Interleukin-4 / Q000235:genetics / Q000276:immunology; D016849:Keratitis, Herpetic / Q000276:immunology* / Q000517:prevention & control*; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D021122:Protein Subunits / Q000235:genetics / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D012668:Trigeminal Ganglion; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D010948:Viral Plaque Assay; D014779:Virus Replication
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D018925:Chemokines; D016207:Cytokines; D022301:Herpes Simplex Virus Vaccines; C508858:IL12A protein, human; D053765:Interleukin-12 Subunit p35; D053762:Interleukin-12 Subunit p40; D021122:Protein Subunits; D014614:Vaccines, Synthetic; D018664:Interleukin-12; D015847:Interleukin-4
Eur J Immunol. 1993 Sep;23(9):2202-8
8103745
Eur J Immunol. 1993 Aug;23(8):1762-70
8102100
J Leukoc Biol. 1994 Feb;55(2):280-8
7905508
J Virol. 1994 Apr;68(4):2118-26
8138996
J Immunol. 1994 Mar 15;152(6):2729-35
7511624
J Virol. 1995 Jan;69(1):334-40
7983727
J Immunol. 1995 Jan 1;154(1):116-27
7527811
Ophthalmology. 1994 Dec;101(12):1871-82
7997323
Eur J Immunol. 1995 Jan;25(1):200-6
7843232
J Exp Med. 1995 Mar 1;181(3):901-14
7869050
J Immunol. 1996 Jan 1;156(1):246-55
8598469
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9085-9
8799158
Ann N Y Acad Sci. 1996 Oct 31;795:1-12
8958912
Immunology. 1997 Jul;91(3):430-5
9301533
Blood. 1997 Oct 1;90(7):2541-8
9326219
Semin Immunol. 1997 Oct;9(5):285-91
9327523
Cancer Res. 1998 Feb 1;58(3):491-9
9458095
Adv Immunol. 1998;70:83-243
9755338
Immunology. 1998 Nov;95(3):352-9
9824497
J Virol. 1999 Jan;73(1):501-9
9847356
J Immunol. 1999 Mar 1;162(5):2912-21
10072541
Curr Top Microbiol Immunol. 1999;238:57-78
10087650
J Infect Dis. 1999 May;179(5):1086-93
10191208
J Immunol. 1999 May 1;162(9):5270-7
10228002
Virology. 1999 Jun 5;258(2):208-16
10366558
J Interferon Cytokine Res. 2000 Mar;20(3):311-9
10762079
Immunity. 2000 Nov;13(5):715-25
11114383
J Leukoc Biol. 2001 Jan;69(1):149-57
11200059
Cancer Gene Ther. 2001 Apr;8(4):269-77
11393279
J Immunol. 2001 Jun 15;166(12):7419-26
11390494
J Virol. 2001 Oct;75(19):9029-36
11533166
J Immunol. 2001 Dec 1;167(11):6097-104
11714768
J Virol. 2002 Jan;76(1):243-50
11739689
Eur J Immunol. 2002 Aug;32(8):2308-16
12209644
Virus Res. 2002 Dec;90(1-2):317-26
12457985
J Immunol. 2002 Dec 15;169(12):7104-10
12471147
Nat Rev Immunol. 2003 Feb;3(2):133-46
12563297
Nature. 2003 Feb 13;421(6924):744-8
12610626
J Virol. 2003 May;77(10):5774-83
12719570
J Virol. 2003 Jun;77(12):6692-9
12767989
Ocul Immunol Inflamm. 2002 Jun;10(2):105-16
12778346
Immunity. 2003 Nov;19(5):641-4
14614851
Invest Ophthalmol Vis Sci. 2004 Feb;45(2):506-14
14744892
J Exp Med. 2004 Apr 5;199(7):1011-6
15051764
Surv Ophthalmol. 1976 Sep-Oct;21(2):121-35
988644
J Immunol. 1983 Jul;131(1):282-7
6190911
Clin Dermatol. 1984 Apr-Jun;2(2):56-66
6443690
J Infect Dis. 1987 May;155(5):914-20
3031173
J Virol. 1987 May;61(5):1571-6
2952807
J Gen Virol. 1987 Jul;68 ( Pt 7):1909-19
3037014
Prog Med Virol. 1987;34:89-128
2821579
J Immunol. 1988 Jan 1;140(1):294-9
2826591
Hematol Oncol Clin North Am. 1989 Sep;3(3):441-52
2698876
Intervirology. 1990;31(2-4):159-65
2373609
J Exp Med. 1990 Aug 1;172(2):487-96
2165127
Science. 1990 Nov 30;250(4985):1262-6
2173860
Immunology. 1990 Nov;71(3):358-63
2176641
J Exp Med. 1991 Apr 1;173(4):869-79
1672545
Virology. 1991 May;182(1):287-97
1850907
J Exp Med. 1992 Nov 1;176(5):1387-98
1357073
Vaccine. 1993;11(6):629-36
8391739
J Immunol. 1994 Feb 1;152(3):1253-64
7905500